460 related articles for article (PubMed ID: 31208705)
1. Low-density lipoprotein cholesterol goal achievement in patients with familial hypercholesterolemia in countries outside Western Europe: The International ChoLesterol management Practice Study.
Blom DJ; Almahmeed W; Al-Rasadi K; Azuri J; Daclin V; Kayikcioglu M; Mercier F; Ruiz AJ; Santos RD;
J Clin Lipidol; 2019; 13(4):594-600. PubMed ID: 31208705
[TBL] [Abstract][Full Text] [Related]
2. LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments.
Rizos CV; Skoumas I; Rallidis L; Skalidis E; Tziomalos K; Garoufi A; Anagnostis P; Sfikas G; Kotsis V; Doumas M; Kolovou G; Lambadiari V; Dima I; Kiouri E; Zacharis E; Agapakis D; Attilakos A; Antza C; Vlachopoulos C; Liberopoulos EN
Int J Cardiol; 2021 Dec; 345():119-124. PubMed ID: 34687802
[TBL] [Abstract][Full Text] [Related]
3. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry.
Vrablik M; Raslová K; Vohnout B; Blaha V; Satny M; Kyselak O; Vaclova M; Urbanek R; Maskova J; Soska V; Freiberger T
Atherosclerosis; 2018 Oct; 277():355-361. PubMed ID: 30270071
[TBL] [Abstract][Full Text] [Related]
4. Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy.
Hartgers ML; Besseling J; Stroes ES; Wittekoek J; Rutten JHW; de Graaf J; Visseren FLJ; Imholz BPM; Roeters van Lennep JE; Huijgen R; Kastelein JJP; Hovingh GK
J Clin Lipidol; 2018; 12(4):972-980.e1. PubMed ID: 29934068
[TBL] [Abstract][Full Text] [Related]
5. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
[TBL] [Abstract][Full Text] [Related]
6. Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia.
Menzin J; Aggarwal J; Boatman B; Yu J; Stern K; Harrison DJ; Patel JG
J Manag Care Spec Pharm; 2017 Dec; 23(12):1270-1276. PubMed ID: 29172973
[TBL] [Abstract][Full Text] [Related]
7. LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C.
van Delden XM; Huijgen R; Wolmarans KH; Brice BC; Barron JK; Blom DJ; Marais AD
Atherosclerosis; 2018 Oct; 277():327-333. PubMed ID: 30270067
[TBL] [Abstract][Full Text] [Related]
8. The therapeutic management of South African dyslipidaemic patients at very high cardiovascular risk (CARDIO TRACK): a cross-sectional study.
Blom DJ; Ranjith N; Joshi P; Naidoo P; van Tonder A; Musa MG; Joshi S; Leisegang R; Trokis JS; Makan H; Raal FJ
Cardiovasc J Afr; 2020; 31(5):245-251. PubMed ID: 33151240
[TBL] [Abstract][Full Text] [Related]
9. Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial.
Nissen SE; Dent-Acosta RE; Rosenson RS; Stroes E; Sattar N; Preiss D; Mancini GB; Ballantyne CM; Catapano A; Gouni-Berthold I; Stein EA; Xue A; Wasserman SM; Scott R; Thompson PD;
Clin Cardiol; 2016 Mar; 39(3):137-44. PubMed ID: 26946077
[TBL] [Abstract][Full Text] [Related]
10. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
11. Efficiency and problems of statin therapy in patients with heterozygous familial hypercholesterolemia.
Korneva V; Kuznetsova T; Julius U
Atheroscler Suppl; 2019 Dec; 40():79-87. PubMed ID: 31818452
[TBL] [Abstract][Full Text] [Related]
12. Prevalence, clinical features and prognosis of familial hypercholesterolemia in Chinese Han patients with acute coronary syndrome after a coronary event: a retrospective observational study.
Kou H; Wang H; Liu P; Wang X; Zhu W; Jiang W; Hu X; Deng J
BMC Cardiovasc Disord; 2024 Mar; 24(1):144. PubMed ID: 38443803
[TBL] [Abstract][Full Text] [Related]
13. Target achievement with maximal statin-based lipid-lowering therapy in Korean patients with familial hypercholesterolemia: A study supported by the Korean Society of Lipid and Atherosclerosis.
Oh J; Lee CJ; Kim DI; Rhee MY; Lee BK; Ahn Y; Cho BR; Woo JT; Hur SH; Jeong JO; Jang Y; Lee SH
Clin Cardiol; 2017 Dec; 40(12):1291-1296. PubMed ID: 29243274
[TBL] [Abstract][Full Text] [Related]
14. Treatment pattern of familial hypercholesterolemia in Slovakia: Targets, treatment and obstacles in common practice.
Vohnout B; Fábryová Ľ; Klabník A; Kadurová M; Bálinth K; Kozárová M; Bugáňová I; Sirotiaková J; Rašlová K
Atherosclerosis; 2018 Oct; 277():323-326. PubMed ID: 30270066
[TBL] [Abstract][Full Text] [Related]
15. Management of High and Very High-Risk Subjects with Familial Hypercholesterolemia: Results from an Observational Study in Bulgaria.
Petrov IS; Postadzhiyan AS; Tokmakova MP; Kitova LG; Tsonev SN; Addison J; Petkova RT; Lachev VI
Folia Med (Plovdiv); 2018 Sep; 60(3):389-396. PubMed ID: 30355848
[TBL] [Abstract][Full Text] [Related]
16. Attainment of Low-Density Lipoprotein Cholesterol Targets and Prescribing Pattern of Lipid-Lowering Medications among Patients with Familial Hypercholesterolemia Attending Specialist Clinics.
Chua YA; Nazli SA; Rosman A; Kasim SS; Ibrahim KS; Md Radzi AB; Mohd Kasim NA; Nawawi H
J Atheroscler Thromb; 2023 Oct; 30(10):1317-1326. PubMed ID: 36567112
[TBL] [Abstract][Full Text] [Related]
17. Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.
Gencer B; Koskinas KC; Räber L; Karagiannis A; Nanchen D; Auer R; Carballo D; Carballo S; Klingenberg R; Heg D; Matter CM; Lüscher TF; Rodondi N; Mach F; Windecker S
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29122809
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of potential familial hypercholesteremia (FH) in 54,811 statin-treated patients in clinical practice.
Catapano AL; Lautsch D; Tokgözoglu L; Ferrieres J; Horack M; Farnier M; Toth PP; Brudi P; Tomassini JE; Ambegaonkar B; Gitt AK
Atherosclerosis; 2016 Sep; 252():1-8. PubMed ID: 27494444
[TBL] [Abstract][Full Text] [Related]
19. Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe.
Ruel I; Aljenedil S; Sadri I; de Varennes É; Hegele RA; Couture P; Bergeron J; Wanneh E; Baass A; Dufour R; Gaudet D; Brisson D; Brunham LR; Francis GA; Cermakova L; Brophy JM; Ryomoto A; Mancini GBJ; Genest J
Clin Chem; 2018 Feb; 64(2):355-362. PubMed ID: 29038147
[TBL] [Abstract][Full Text] [Related]
20. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.
Perez de Isla L; Alonso R; Watts GF; Mata N; Saltijeral Cerezo A; Muñiz O; Fuentes F; Diaz-Diaz JL; de Andrés R; Zambón D; Rubio-Marin P; Barba-Romero MA; Saenz P; Sanchez Muñoz-Torrero JF; Martinez-Faedo C; Miramontes-Gonzalez JP; Badimón L; Mata P;
J Am Coll Cardiol; 2016 Mar; 67(11):1278-85. PubMed ID: 26988947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
